Tags : Aged≥ 65yrs.

Sanofi’s Fluzone High-Dose Quadrivalent (Influenza Vaccine) Receives the FDA’s Approval

Tuba Khan November 5, 2019

Shots: The sBLA approval is based on P-III immunogenicity and safety study assessing Fluzone High-Dose Quadrivalent vs two trivalent formulations of Fluzone High-Dose in 32,000 adults aged≥ 65yrs. over two influenza seasons […]readmore

Tags : Aged≥ 65yrs.

Sanofi’s Fluzone High-Dose Quadrivalent (Influenza Vaccine) Receives the FDA’s Approval

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Aged≥ 65yrs.

Sanofi’s Fluzone High-Dose Quadrivalent (Influenza Vaccine) Receives the FDA’s Approval

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company